Letter from GlaxoWellcome to CIPLA:
Importation of Duovir into Uganda


20th November, 2000

Cipla Ltd
Mumbai Central
Mumbai 400 008

FAO: Mr Amar Lulla, Director,

Dear Sirs,

Re: Lamivudine and Zidovudine

It has come to our attention that you have imported products containing lamivudine and zidovudine into Uganda and offered the same for sale.

Glaxo Group Limited has exclusive rights under the following patents that cover lamivudine and zidovudine formulations in Uganda: AP11, AP136, AP182, AP300.

Importation, sale or offering for sale of products containing lamivudine and zidovudine in Uganda by Cipla or any of its affiliates represents an infringement of our Company's exclusive patent rights.

Intellectual property protection is essential to sustain the investment needed for discovery and development of new treatments fo HIV/AIDS and other diseases affecting the developing world. Intellectual property protection is also critical to expanding the global response to HIV/AIDS, including ensuring successful and sustainable public-private partnerships such as the UN-led, nationally-driven Accelerating Access initiative. Uganda has been included in the first wave country partners in this new international impetus for HIV/AIDS prevention, treatment, and care.

I look forward to your assurance that you will cease all infringing activity in Uganda and respect the above mentioned patent rights.

Yours faithfully,

G. G. Brereton
Head of Patents
Global Intellectual Property Department

| CPT Health Care Page | CPT Country Dispute page | CPT Africa page |